Yoshinobu Konishi

Has grant

Assistant Professor

Kyoto University Hospital
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Grant-in-Aid for Early-Career Scientists

Open Date: 2020-04-01

Close Date: 2023-03-01

Grant: Close

The Japan Society for the Promotion of Science Research Fellow (PD)

Open Date: 2020-04-01

Close Date: 2023-03-01

Grant: Close

Grant-in-Aid for Research Activity Start-up

Open Date: 2019-04-01

Close Date: 2020-03-01

Grant: Close

Grant-in-Aid for JSPS Fellows

Open Date: 2016-04-01

Close Date: 2019-03-01

Grant: Close

The Japan Society for the Promotion of Science Research Fellow (DC1)

Open Date: 2016-04-01

Close Date: 2019-03-01

Articles (5)

Year:

2025

Year:

2025

Background DNA cytosine deaminase APOBEC3B (A3B) is one of the endogenous sources of somatic mutations in many types of human cancers and is associated with tumor progression rather than tumorigenesis. However, it remains uncertain whether APOBEC3B‐induced mutations accelerate tumor progression or not. In this paper, we established a mouse model with A3B overexpression and investigated whether the introduction of A3B overexpression accelerates tumor development in Tp53 hemizygous mice. Methods We established A3B transgenic mouse by microinjection and selected the mouse which has only one A3B transgene by genomic qPCR and southern blotting using the probe against the transgene. A3B expression was validated by qPCR, immunoblotting, immunohistochemistry and in vitro CDA assays using lysates of this transgenic mouse liver, spleen and bone marrow. We interbreed this transgenic mouse model with CAG‐Cre and Tp53 knockout mice and observed differences in tumor progression and survival between Tp53 hemizygous mice and Tp53 homozygous mice irrespective of A3B expression. Finally, comprehensive genomic mutation analysis was done using the developed tumors. Results We established A3B transgenic mouse which has only one transgene. A3B expression and its CDA activity were confirmed in liver cells and tumor tissues of mice overexpressing A3B. Tp53 hemizygous mice developed osteosarcomas, spindle and pleomorphic sarcomas, and squamous cell carcinomas, however we did not observe any difference in tumor development between the mice with or without A3B expression. The tumor with A3B expression has more high‐VAF mutations than the one without A3B, but these mutations are not APOBEC signature. Conclusion We developed a Cre inducible A3B transgenic mouse model bearing single copy of A3B gene. Although the introduction of A3B overexpression did not accelerate tumor development in Tp53 hemizygous mice, our mouse model with A3B overexpression is well‐validated and useful for further research.

Year:

2025

Year:

2023

Year:

2023

Collaborators (5)

Hiroyuki Matsui

Assistant Professor

Kyoto University Hospital

JAPAN
View details

Hong Yue

Dana-Farber Cancer Institute

UNITED STATES
View details

Nicholas Haradhvala

Broad Institute

UNITED STATES
View details

Jean-Baptiste Alberge

Institut Gustave Roussy

FRANCE
View details

Michelle Aranha

Computational Scientist

Broad Institute

UNITED STATES
View details